Evidence map›Paper›PMID 28173629›Full record

ArticleMolecular oncology2017

Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.

Murugan Kalimutho, Amanda L Bain, Bipasha Mukherjee, Purba Nag, Devathri M Nanayakkara, Sarah K Harten, Janelle L Harris, Goutham N Subramanian, Debottam Sinha, Senji Shirasawa and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Expressions of HELQ and RAD51C in endometrial stromal sarcoma and their clinical significance].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  15. Article
  16. Article
  17. Frontiers in molecular biosciences · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Murugan KalimuthoSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Amanda L BainSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Bipasha MukherjeeDivision of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Purba NagSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Devathri M NanayakkaraSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Sarah K HartenSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Janelle L HarrisSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Goutham N SubramanianSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Debottam SinhaSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Senji ShirasawaDepartment of Cell Biology, Faculty of Medicine, Fukuoka University, Japan.
Sriganesh SrihariInstitute for Molecular Bioscience, The University of Queensland, St. Lucia, Australia.
Sandeep BurmaDivision of Molecular Radiation Biology, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Kum Kum KhannaSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
QIMR Berghofer Medical Research Institute · AUGriffith University · AUThe University of Texas Southwestern Medical Center · USFukuoka University · JPUniversity of Queensland · AU

Funding

Molecular mechanisms of GBM radioresistance and strategies for radiosensitizationR01CA149461 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BURMA, SANDEEP · 2011 to 2015
$1.6M
Mechanisms of EXO1 regulation in response to radiation-induced DNA damageR01CA197796 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BURMA, SANDEEP · 2016 to 2020
$1.6M
Augmented homologous recombination as a mechanism of acquired temozolomide resistance in glioblastomaR21CA202403 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BURMA, SANDEEP · 2016 to 2017
$388k
NCI NIH HHS R01 CA149461NCI NIH HHS R01 CA197796NCI NIH HHS R21 CA202403
6 · The paper itself

Abstract

Activating KRAS mutations drive colorectal cancer tumorigenesis and influence response to anti-EGFR-targeted therapy. Despite recent advances in understanding Ras signaling biology and the revolution in therapies for melanoma using BRAF inhibitors, no targeted agents have been effective in KRAS-mutant cancers, mainly due to activation of compensatory pathways. Here, by leveraging the largest synthetic lethal genetic interactome in yeast, we identify that KRAS-mutated colorectal cancer cells have augmented homologous recombination repair (HRR) signaling. We found that KRAS mutation resulted in slowing and stalling of the replication fork and accumulation of DNA damage. Moreover, we found that KRAS-mutant HCT116 cells have an increase in MYC-mediated RAD51 expression with a corresponding increase in RAD51 recruitment to irradiation-induced DNA double-strand breaks (DSBs) compared to genetically complemented isogenic cells. MYC depletion using RNA interference significantly reduced IR-induced RAD51 foci formation and HRR. On the contrary, overexpression of either HA-tagged wild-type (WT) MYC or phospho-mutant S62A increased RAD51 protein levels and hence IR-induced RAD51 foci. Likewise, depletion of RAD51 selectively induced apoptosis in HCT116-mutant cells by increasing DSBs. Pharmacological inhibition targeting HRR signaling combined with PARP inhibition selectivity killed KRAS-mutant cells. Interestingly, these differences were not seen in a second isogenic pair of KRAS WT and mutant cells (DLD-1), likely due to their nondependency on the KRAS mutation for survival. Our data thus highlight a possible mechanism by which KRAS-mutant-dependent cells drive HRR in vitro by upregulating MYC-RAD51 expression. These data may offer a promising therapeutic vulnerability in colorectal cancer cells harboring otherwise nondruggable KRAS mutations, which warrants further investigation in vivo.

Indexed as

Homologous RecombinationAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDNA-Binding ProteinsDNA Breaks, Double-StrandedDNA DamageDose-Response Relationship, DrugErbB ReceptorsHCT116 CellsHumansMutationPoly(ADP-ribose) Polymerase InhibitorsProto-Oncogene Proteins p21(ras)Rad51 RecombinaseRNA, Small InterferingAntineoplastic AgentsDNA-Binding ProteinsEGFR protein, humanErbB ReceptorsKRAS protein, humanMYCBP protein, humanPoly(ADP-ribose) Polymerase InhibitorsProto-Oncogene Proteins p21(ras)RAD51 protein, humanRad51 RecombinaseRNA, Small InterferingTranscription Factorscolorectal cancerDNA damage responsehomologous recombination repairKRASRAD51therapeutic vulnerability

Identifiers

PMID28173629
PMCPMC5527460
OpenAlexW2586917786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.